STOCK TITAN
  1. Home
  2. News
  3. ICAD

Icad Inc - ICAD STOCK NEWS

Welcome to our dedicated news page for Icad (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Icad's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Icad's position in the market.

News
iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) will participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 12-14, 2024. CEO Dana Brown and CFO Eric Lonnqvist will engage in one-on-one meetings with investors. iCAD is a global leader in AI-powered solutions for cancer detection, aiming to improve patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences
-
News
iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member
Rhea-AI Summary
iCAD, Inc. appoints Michael J. Doyle, a seasoned technology and healthcare executive, to its Board of Directors. Mr. Doyle's extensive experience in AI-enabled healthcare platforms and global business strategy is expected to bring valuable expertise to iCAD. The company aims to continue developing and delivering innovative AI-powered solutions to improve patient outcomes worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
management
-
News
iCAD Expands Executive Sales Leadership Team as Business Grows
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) expands its sales leadership with the addition of Peter Graham as Senior Vice President, North American Sales, and a role change for Bill Keyes to Senior Vice President, Global Sales Operations. The company aims to drive growth, increase revenue, and deliver results by introducing new solutions under the ProFound Breast Health Suite portfolio and launching programs with new partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
management
News
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
Rhea-AI Summary
iCAD, Inc. (ICAD) announces integration of key AI applications from its ProFound Breast Health Suite with GE HealthCare’s new MyBreastAI Suite, aimed at streamlining workflow and supporting clinicians in delivering personalized breast care. The AI solutions aim to enhance breast cancer detection and diagnosis while optimizing workflow efficiency to elevate patient care outcomes globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.6%
Tags
AI
-
News
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) presents new research at RSNA annual meeting showcasing the ProFound Breast Health Suite's ability to predict a woman’s one to two-year risk for breast cancer and assess calcium deposits in the breast arteries as a proxy for hidden cardiovascular disease. The AI-powered solution improves cancer detection rates, reduces false positive results, and accurately evaluates a woman’s breast density and cancer risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
AI
-
News
iCAD and CancerIQ Announce Partnership to Integrate AI-Enabled Technology With Best-in-Class Risk Assessment and Care Management Platform Offering A Comprehensive Breast Health Care Solution  
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) and CancerIQ announced a partnership to provide a comprehensive breast health care solution, combining iCAD's ProFound Breast Health Suite with CancerIQ's precision cancer prevention platform. The partnership aims to inform physicians and patients of cancer risk, identify breast cancer at earlier stages, and increase patient adherence to personalized care plans. By integrating AI-informed 1- or 2-year risk with lifetime risk, the solutions offer a 2.4x more accurate prediction of breast cancer risk. The partnership announcement coincides with iCAD's appearance at the Radiological Society of North America (RSNA) annual meeting in Chicago, unveiling new research using AI in breast cancer risk detection and heart disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
partnership AI
News
iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) Announces Participation at the 14th Annual Craig-Hallum Alpha Select Conference. The company's President and CEO, Dana Brown, and CFO, Eric Lonnqvist, will be attending the conference to host one-on-one meetings with investors and attendees. The event will take place at the Sheraton New York Times Square in New York City, offering an opportunity for investors to connect with the company's management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.99%
Tags
conferences
-
News
iCAD Reports Financial Results for Third Quarter Ended September 30, 2023
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) reports Q3 financial results, re-introduces Annual Recurring Revenue (ARR) metrics, and completes sale of Xoft, focusing on AI-powered breast health solutions. The company plans to host a conference call and webcast today at 4:30 PM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.99%
Tags
earnings
-
News
iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023
Rhea-AI Summary
iCAD, Inc. will release its financial results for the third quarter ended September 30, 2023, after the market close. The company is a global leader in AI-powered breast health solutions. A conference call will be held on November 13, 2023, at 4:30 PM Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
conferences earnings
News
iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta
Rhea-AI Summary
Elekta acquires Xoft, a subsidiary of iCAD, Inc., for $5.5 million to expand access to electronic brachytherapy technology for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
Stock ICAD logo
Icad Inc

Nasdaq:ICAD

ICAD Rankings

#4861 Ranked by Market Cap
#3880 Ranked by Stock Gains
N/A Ranked by Dividends

ICAD Stock Data

44.54M
24.81M
5.82%
28.53%
1.71%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States
Nashua

About ICAD

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.